Format

Send to

Choose Destination
Int J Tuberc Lung Dis. 2015 May;19(5):517-24. doi: 10.5588/ijtld.14.0535.

High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.

Author information

1
Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaoundé, Cameroon; Faculty of Health Sciences, University of Bamenda, Bamenda, Cameroon.
2
Independent consultant, Yaoundé, Cameroon.
3
International Union Against Tuberculosis and Lung Disease, Paris, France; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
4
International Union Against Tuberculosis and Lung Disease, Paris, France.
5
National Tuberculosis Control Programme, Yaoundé, Cameroon.

Abstract

SETTING:

Two specialised multidrug-resistant tuberculosis (MDR-TB) treatment units in Cameroon.

OBJECTIVE:

To assess outcome and adverse drug events with a standardised 12-month regimen for MDR-TB among second-line drug naïve patients.

DESIGN:

Prospective observational study of MDR-TB patients treated with a standardised 12-month regimen including gatifloxacin, clofazimine, prothionamide, ethambutol and pyrazinamide throughout, supplemented by kanamycin and isoniazid during an intensive phase of a minimum of 4 months. Progress was monitored monthly until treatment completion and twice over one year after treatment cessation.

RESULTS:

Eighty-seven potentially eligible patients were lost and never treated due to delayed availability of test results. Among the 150/236 eligible and treated patients, 134 (89%) successfully completed treatment, 10 died, 5 were lost, 1 failed and none relapsed. The patients' mean age was 33.7 years (range 17-68), 73 (49%) were females, 120 (80%) had failed on previous treatment, 30 (20%) were human immunodeficiency virus seropositive, 62 (43%) had a body mass index <18.5 kg/m(2) and 41 (27%) had radiographic involvement of five or six of the six lung zones. The most important adverse drug event was hearing impairment, which occurred in 46 of 106 (43%) patients.

CONCLUSIONS:

These results add further evidence for the usefulness of shorter, standardised regimens among patients without second-line drug resistance.

PMID:
25868018
DOI:
10.5588/ijtld.14.0535
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center